Abstract
The human and monetary costs of chronic hepatitis C and the complications arising from this disease emphasize the urgency to find a treatment for Hepatitis C Virus (HCV) infected patients. The current standard of treatment for patients chronically infected with HCV is combination therapy with pegylated interferon plus ribavirin. Recently, viral enzymes have become the target of efforts to develop small molecule inhibitors interfering with the essential steps in the life cycle of the virus. Amongst these enzymes the HCV-encoded NS5B RNA-dependent RNA polymerase (NS5B RdRp) is essential for viral replication and has been recognized as a prime target for therapeutic intervention. Several distinct classes of inhibitors of NS5B RdRp have been disclosed in the literature, including active site inhibitors such as nucleosides and pyrophosphate mimetics, as well as non-nucleoside inhibitors. The latter, based on the success of allosteric inhibitors in the treatment of HIV infection, have been developed into compounds which show activity in the subgenomic cell-culture assay of HCV replication. This review provides an account of the recent developments in this field.
Keywords: Allosteric inhibition, Hepatitis C virus, RNA polymerase, sub-genomic replicon
Infectious Disorders - Drug Targets
Title: Allosteric Inhibition of the Hepatitis C Virus NS5B RNA Dependent RNA Polymerase
Volume: 6 Issue: 1
Author(s): Uwe Koch and Frank Narjes
Affiliation:
Keywords: Allosteric inhibition, Hepatitis C virus, RNA polymerase, sub-genomic replicon
Abstract: The human and monetary costs of chronic hepatitis C and the complications arising from this disease emphasize the urgency to find a treatment for Hepatitis C Virus (HCV) infected patients. The current standard of treatment for patients chronically infected with HCV is combination therapy with pegylated interferon plus ribavirin. Recently, viral enzymes have become the target of efforts to develop small molecule inhibitors interfering with the essential steps in the life cycle of the virus. Amongst these enzymes the HCV-encoded NS5B RNA-dependent RNA polymerase (NS5B RdRp) is essential for viral replication and has been recognized as a prime target for therapeutic intervention. Several distinct classes of inhibitors of NS5B RdRp have been disclosed in the literature, including active site inhibitors such as nucleosides and pyrophosphate mimetics, as well as non-nucleoside inhibitors. The latter, based on the success of allosteric inhibitors in the treatment of HIV infection, have been developed into compounds which show activity in the subgenomic cell-culture assay of HCV replication. This review provides an account of the recent developments in this field.
Export Options
About this article
Cite this article as:
Koch Uwe and Narjes Frank, Allosteric Inhibition of the Hepatitis C Virus NS5B RNA Dependent RNA Polymerase, Infectious Disorders - Drug Targets 2006; 6 (1) . https://dx.doi.org/10.2174/187152606776056724
DOI https://dx.doi.org/10.2174/187152606776056724 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) An Overwiev of ORF Virus Infection in Humans and Animals
Recent Patents on Anti-Infective Drug Discovery Furosemide Protective Effect Against Airway Obstruction
Current Drug Targets Microfluidic Methods for Non-Viral Gene Delivery
Current Gene Therapy Pain and Obesity in the Older Adult
Current Pharmaceutical Design Hematopoietic Cytokines - on the Verge of Conquering Neurology
Current Molecular Medicine The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Evaluating the Effect of Oral N-acetylcysteine as an Adjuvant Treatment on Clinical Outcomes of Patients with Rheumatoid Arthritis: A Randomized, Double Blind Clinical Trial
Reviews on Recent Clinical Trials A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets The Potential of Hydrogen for Improving Mental Disorders
Current Pharmaceutical Design The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients
Current Drug Discovery Technologies New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Developmental and Biological Insights Obtained from Gene Expression Profiling of the Nematode Caenorhabditis Elegans
Current Genomics An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research
Current Drug Abuse Reviews Novel Systemic Markers for Patients with Alzheimer Disease? – A Pilot Study
Current Alzheimer Research The Colostrum Proteome, Ruminant Nutrition and Immunity: A Review
Current Protein & Peptide Science Extracellular Matrix Fragments as Regulators of Cartilage Metabolism in Health and Disease
Current Rheumatology Reviews Anti-Infective Strategies of the Future: Is there Room for Species-Specific Antibacterial Agents?
Current Pharmaceutical Design Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery